Scribd Logo
Upload

Welcome to Scribd!

  • CADYRETA ®nesiritide Injection, Powder, Lyophilized, For Solution TAJ PHARMA

    Uploaded by

    Anonymous bkUDjSjUD
    5 views2 pages
    CADYRETA ®nesiritide injection, powder, lyophilized, for solution CADYRETA ®nesiritide injection, powder, lyophilized, for solution Treats congestive heart failure (CHF) that is getting worse and causing breathing problems. What is nesiritide? Nesiritide relaxes and dilates blood vessels, lowering blood pressure. Nesiritide is used to improve breathing in people with congestive heart failure (CHF). Nesiritide may also be used for purposes not listed in this medication guide. Nesiritide dosing information Usual Adult Dose for Congestive Heart Failure: Initial dose: 2 mcg/kg IV bolus, followed by 0.01 mcg/kg/min via continuous IV infusion; not to be titrated more frequently than every 3 hours to a maximum of 0.03 mcg/kg/min Comments: -This drug should not be initiated at a dose higher than the initial recommended dose. -The loading dose may not be appropriate for those with systolic blood pressure less than 110 mmHg or for patients recently treated with afterload reducers. -There is limited experience with administering this drug for longer than 96 hours; monitor blood pressure closely during administration. Use: For the treatment of acutely decompensated heart failure in patients who have dyspnea at rest or with minimal activity What are the possible side effects of nesiritide CADYRETA Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat. Tell your caregivers at once if you have: confusion, feeling light-headed, fainting; fast, slow, or irregular heartbeats; urinating less than usual; chest pain; or fever, unusual weakness or tiredness. Other common side effects may include: headache, mild dizziness; nausea, vomiting; back pain; numbness or tingly... [1.5 mg] [250 ml] Restrictions: Restricted to Cardiology Consult Preparation: Reconstitute one 1.5-mg vial of Natrecor by adding 5 mL of diluent removed from a pre-filled 250-mL plastic IV bag containing the diluent of choice. The following preservative-free diluents are recommended for reconstitution: 5% Dextrose Injection (D5W), USP; 0.9% Sodium Chloride Injection, USP; 5% Dextrose and 0.45% Sodium Chloride Injection, USP, or 5% Dextrose and 0.2% Sodium Chloride Injection, USP. Do not shake the vial. Rock the vial gently so that all surfaces, including the stopper, are in contact with the diluent to ensure complete reconstitution. Use only a clear, essentially colorless solution. The IV bag should be inverted several times to ensure complete mixing of the solution. Label: Monitor BP closely. Stability: (reconstituted vials / solutions): 24 hours RT or REF. Dosing: IV bolus of 2 µg/kg (over 1 minute) followed by a continuous infusion of 0.01 mcg/kg/min. Withdraw bolus dose from the infusion bag. Higher initial dosages are not recommended. Calculation: Bolus Volume (ml) = 0.33 × Patient Wt (kg). Infusion Rate (ml/hr) = 0.1 × Patient wt (kg). There is limited experience with administering Natrecor for longer than 48 hours. Indications: IV treatment of patients with acutely decompensated CHF who have dyspnea at rest or with minimal activity. Actions: venous and arterial vasodilation (decreased PCWP etc), plus mild diuretic effect. Mechanism of Action Human BNP binds to the particulate guanylate cyclase receptor of vascular smooth muscle and endothelial cells, leading to increased intracellular concentrations of guanosine 3'5'-cyclic monophosphate (cGMP) and smooth muscle cell relaxation. Cyclic GMP serves as a second messenger to dilate veins and arteries. Nesiritide has been shown to relax isolated human arterial and venous tissue preparations that were precontracted with either endothelin-1 or the alpha-adrenergic agonist, phenylephrine. In human studies, nesiritide produced dose-dependent reductions in pulmonary capillary wedge pressure (PCWP) and systemic arterial pressure i

    Original Title

    CADYRETA ®nesiritide injection, powder, lyophilized, for solution TAJ PHARMA

    Copyright

    © © All Rights Reserved

    Available Formats

    PDF, TXT or read online from Scribd

    Did you find this document useful?

    Is this content inappropriate?

    Report this Document
    CADYRETA ®nesiritide injection, powder, lyophilized, for solution CADYRETA ®nesiritide injection, powder, lyophilized, for solution Treats congestive heart failure (CHF) that is getting worse and causing breathing problems. What is nesiritide? Nesiritide relaxes and dilates blood vessels, lowering blood pressure. Nesiritide is used to improve breathing in people with congestive heart failure (CHF). Nesiritide may also be used for purposes not listed in this medication guide. Nesiritide dosing information Usual Adult Dose for Congestive Heart Failure: Initial dose: 2 mcg/kg IV bolus, followed by 0.01 mcg/kg/min via continuous IV infusion; not to be titrated more frequently than every 3 hours to a maximum of 0.03 mcg/kg/min Comments: -This drug should not be initiated at a dose higher than the initial recommended dose. -The loading dose may not be appropriate for those with systolic blood pressure less than 110 mmHg or for patients recently treated with afterload reducers. -There is limited experience with administering this drug for longer than 96 hours; monitor blood pressure closely during administration. Use: For the treatment of acutely decompensated heart failure in patients who have dyspnea at rest or with minimal activity What are the possible side effects of nesiritide CADYRETA Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat. Tell your caregivers at once if you have: confusion, feeling light-headed, fainting; fast, slow, or irregular heartbeats; urinating less than usual; chest pain; or fever, unusual weakness or tiredness. Other common side effects may include: headache, mild dizziness; nausea, vomiting; back pain; numbness or tingly... [1.5 mg] [250 ml] Restrictions: Restricted to Cardiology Consult Preparation: Reconstitute one 1.5-mg vial of Natrecor by adding 5 mL of diluent removed from a pre-filled 250-mL plastic IV bag containing the diluent of choice. The following preservative-free diluents are recommended for reconstitution: 5% Dextrose Injection (D5W), USP; 0.9% Sodium Chloride Injection, USP; 5% Dextrose and 0.45% Sodium Chloride Injection, USP, or 5% Dextrose and 0.2% Sodium Chloride Injection, USP. Do not shake the vial. Rock the vial gently so that all surfaces, including the stopper, are in contact with the diluent to ensure complete reconstitution. Use only a clear, essentially colorless solution. The IV bag should be inverted several times to ensure complete mixing of the solution. Label: Monitor BP closely. Stability: (reconstituted vials / solutions): 24 hours RT or REF. Dosing: IV bolus of 2 µg/kg (over 1 minute) followed by a continuous infusion of 0.01 mcg/kg/min. Withdraw bolus dose from the infusion bag. Higher initial dosages are not recommended. Calculation: Bolus Volume (ml) = 0.33 × Patient Wt (kg). Infusion Rate (ml/hr) = 0.1 × Patient wt (kg). There is limited experience with administering Natrecor for longer than 48 hours. Indications: IV treatment of patients with acutely decompensated CHF who have dyspnea at rest or with minimal activity. Actions: venous and arterial vasodilation (decreased PCWP etc), plus mild diuretic effect. Mechanism of Action Human BNP binds to the particulate guanylate cyclase receptor of vascular smooth muscle and endothelial cells, leading to increased intracellular concentrations of guanosine 3'5'-cyclic monophosphate (cGMP) and smooth muscle cell relaxation. Cyclic GMP serves as a second messenger to dilate veins and arteries. Nesiritide has been shown to relax isolated human arterial and venous tissue preparations that were precontracted with either endothelin-1 or the alpha-adrenergic agonist, phenylephrine. In human studies, nesiritide produced dose-dependent reductions in pulmonary capillary wedge pressure (PCWP) and systemic arterial pressure i

    Copyright:

    © All Rights Reserved
    Download as PDF, TXT or read online from Scribd
    Flag for inappropriate content
    5 views2 pages

    CADYRETA ®nesiritide Injection, Powder, Lyophilized, For Solution TAJ PHARMA

    Uploaded by

    Anonymous bkUDjSjUD
    CADYRETA ®nesiritide injection, powder, lyophilized, for solution CADYRETA ®nesiritide injection, powder, lyophilized, for solution Treats congestive heart failure (CHF) that is getting worse and causing breathing problems. What is nesiritide? Nesiritide relaxes and dilates blood vessels, lowering blood pressure. Nesiritide is used to improve breathing in people with congestive heart failure (CHF). Nesiritide may also be used for purposes not listed in this medication guide. Nesiritide dosing information Usual Adult Dose for Congestive Heart Failure: Initial dose: 2 mcg/kg IV bolus, followed by 0.01 mcg/kg/min via continuous IV infusion; not to be titrated more frequently than every 3 hours to a maximum of 0.03 mcg/kg/min Comments: -This drug should not be initiated at a dose higher than the initial recommended dose. -The loading dose may not be appropriate for those with systolic blood pressure less than 110 mmHg or for patients recently treated with afterload reducers. -There is limited experience with administering this drug for longer than 96 hours; monitor blood pressure closely during administration. Use: For the treatment of acutely decompensated heart failure in patients who have dyspnea at rest or with minimal activity What are the possible side effects of nesiritide CADYRETA Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat. Tell your caregivers at once if you have: confusion, feeling light-headed, fainting; fast, slow, or irregular heartbeats; urinating less than usual; chest pain; or fever, unusual weakness or tiredness. Other common side effects may include: headache, mild dizziness; nausea, vomiting; back pain; numbness or tingly... [1.5 mg] [250 ml] Restrictions: Restricted to Cardiology Consult Preparation: Reconstitute one 1.5-mg vial of Natrecor by adding 5 mL of diluent removed from a pre-filled 250-mL plastic IV bag containing the diluent of choice. The following preservative-free diluents are recommended for reconstitution: 5% Dextrose Injection (D5W), USP; 0.9% Sodium Chloride Injection, USP; 5% Dextrose and 0.45% Sodium Chloride Injection, USP, or 5% Dextrose and 0.2% Sodium Chloride Injection, USP. Do not shake the vial. Rock the vial gently so that all surfaces, including the stopper, are in contact with the diluent to ensure complete reconstitution. Use only a clear, essentially colorless solution. The IV bag should be inverted several times to ensure complete mixing of the solution. Label: Monitor BP closely. Stability: (reconstituted vials / solutions): 24 hours RT or REF. Dosing: IV bolus of 2 µg/kg (over 1 minute) followed by a continuous infusion of 0.01 mcg/kg/min. Withdraw bolus dose from the infusion bag. Higher initial dosages are not recommended. Calculation: Bolus Volume (ml) = 0.33 × Patient Wt (kg). Infusion Rate (ml/hr) = 0.1 × Patient wt (kg). There is limited experience with administering Natrecor for longer than 48 hours. Indications: IV treatment of patients with acutely decompensated CHF who have dyspnea at rest or with minimal activity. Actions: venous and arterial vasodilation (decreased PCWP etc), plus mild diuretic effect. Mechanism of Action Human BNP binds to the particulate guanylate cyclase receptor of vascular smooth muscle and endothelial cells, leading to increased intracellular concentrations of guanosine 3'5'-cyclic monophosphate (cGMP) and smooth muscle cell relaxation. Cyclic GMP serves as a second messenger to dilate veins and arteries. Nesiritide has been shown to relax isolated human arterial and venous tissue preparations that were precontracted with either endothelin-1 or the alpha-adrenergic agonist, phenylephrine. In human studies, nesiritide produced dose-dependent reductions in pulmonary capillary wedge pressure (PCWP) and systemic arterial pressure i

    Copyright:

    © All Rights Reserved
    Download as PDF, TXT or read online from Scribd
    Flag for inappropriate content
    of 2

    www.tajpharma.

    com

    Life With
    CADYRETA

    Rx only

    CADYRETA

    NEW

    Nesiritide Injection, Powder, Lyophilized, For Solution


    FOR INTRAVENOUS INFUSION ONLY
    Treats congestive heart failure (CHF) that is getting worse and
    causing breathing problems.
    What is nesiritide?
    Nesiritide relaxes and dilates blood vessels, lowering blood pressure.
    Nesiritide is used to improve breathing in people with congestive heart failure (CHF).
    Nesiritide may also be used for purposes not listed in this medication guide.

    Nesiritide dosing information


    Usual Adult Dose for Congestive Heart Failure:
    Initial dose: 2 mcg/kg IV bolus, followed by 0.01 mcg/kg/min via continuous IV infusion; not to be titrated
    more frequently than every 3 hours to a maximum of 0.03 mcg/kg/min
    Comments:
    -This drug should not be initiated at a dose higher than the initial recommended dose.
    -The loading dose may not be appropriate for those with systolic blood pressure less than 110 mmHg or
    for patients recently treated with afterload reducers.
    -There is limited experience with administering this drug for longer than 96 hours; monitor blood pressure closely during administration.
    Use: For the treatment of acutely decompensated heart failure in patients who have dyspnea at rest or with minimal activity

    You might also like